Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell ...
An expert interview explores the scientific necessity of patient experience data in amyotrophic lateral sclerosis drug ...
Nurse practitioner Melissa Mavis, APRN, has joined UK King’s Daughters Neurology, where she provides care for patients with ...
Strategic collaboration combines Nurix’s leadership in targeted protein degradation with Roche’s portfolio of B-cell targeted ...
Experts break down whether listening to audiobooks or reading a print book is better for your brain health as you age.
IU Health will soon roll out an app to help diagnose stroke symptoms, with a central goal to help Spanish-speaking patients.
Adults with MS had lower annualized relapse rates with diroximel fumarate vs. dimethyl fumarate treatment at 1 and 2 years, ...
Poor sleep behaviors, such as daytime napping and short sleep duration, are linked to greater white matter hyperintensity volume in older adults.
Roche collaborates with Nurix on bexobrutideg, a BTK degrader for blood cancers, while expanding potential use into ...
Bexobrutideg leverages targeted protein degradation to eliminate BTK, potentially overcoming resistance mutations and ...
Roche is paying Nurix Therapeutics $700 million upfront for rights to bexobrutideg, securing a stake in a BTK degrader that ...
Strategic collaboration combines Nurix's leadership in targeted protein degradation with Roche's portfolio of B-cell targeted therapies and global clinical and commercialization footprint Robust clini ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results